Moderna Inc. completed the enrollment of 30,000 participants in a late-stage study testing the company’s experimental coronavirus vaccine, with over a third of the participants from communities of color.
Enrollment in the 30,000-volunteer U.S. trial testing a Covid-19 vaccine from Pfizer and German partner BioNTech is more than 50 percent complete, according to a top Pfizer vaccine research and development scientist.
Companies Face Challenge of Enrolling Patients in COVID-19 Vaccine Studies Published: July 6, 2020 By Mark Terry BioSpace As of June 29, there were 13 vaccines against COVID-19 in […]
Maryland-based Novavax enrolled and dosed the company’s first patients in a Phase I/II study for a COVID-19 vaccine candidate.
A trial in China testing Gilead Sciences Inc.’s antiviral drug remdesivir in those with mild symptoms of COVID-19 was suspended due to a lack of eligible patients, according to a website maintained by the U.S. government.
A quantitative survey conducted by Continuum Clinical shows clinical research study sites are rapidly becoming more concerned about COVID-19-related interruptions to clinical trial recruitment and retention, with U.S. site concern jumping from 25 percent to 47 percent – an 88 percent increase over just 4 days.
Rafael Pharmaceuticals Inc. reached an enrollment milestone of more than 250 patients in the company’s pivotal Phase 3 clinical trial for metastatic pancreatic cancer (AVENGER 500), which is evaluating the efficacy and safety of Rafael’s lead compound CPI-613 (devimistat) in combination with modified FOLFIRINOX (mFFX) as first-line therapy.
